Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients with Inflammatory Bowel Disease

Gastroenterology

Volumn 149, Issue 6, 2015, Pages 1564-1574.e3

  Biancheri, Paolo ^a,b   Brezski, Randall J ^c   Di Sabatino, Antonio ^b   Greenplate, Allison R ^c   Soring, Keri L ^c   Corazza, Gino R ^b   Kok, Klaartje B ^a   Rovedatti, Laura ^b   Vossenkämper, Anna ^a   Ahmad, Nadja ^a   Snoek, Susanne A ^a   Vermeire, Severine ^d   Rutgeerts, Paul ^d   Jordan, Robert E ^c   Macdonald, Thomas T ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

CD; Inflammation; Therapy; UC

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; ETANERCEPT; GELATINASE B; IMMUNOGLOBULIN G; INFLIXIMAB; MACROPHAGE ELASTASE; MARIMASTAT; STROMELYSIN; BIOLOGICAL FACTOR; EPITOPE; MMP12 PROTEIN, HUMAN; MMP3 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFECT; DRUG RESPONSE; ENZYME ACTIVITY; FEMALE; HELA CELL LINE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOGLOBULIN BLOOD LEVEL; INTESTINE MUCOSA; LUCIFERASE ASSAY; MALE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN FUNCTION; REMISSION; ULCERATIVE COLITIS; BIOPSY; CASE CONTROL STUDY; COLITIS, ULCERATIVE; COLON; DRUG EFFECTS; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ADALIMUMAB; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL FACTORS; BIOPSY; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; EPITOPES; ETANERCEPT; FEMALE; HUMANS; IMMUNOBLOTTING; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; INTESTINAL MUCOSA; MALE; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PROTEOLYSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84945492721     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.07.002     Document Type: Article

References (37)

1. A. Kuek, B.L. Hazleman, and A.J. Ostör Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution Postgrad Med J 83 2007 251 260
2. C.A. Siegel, and G.Y. Melmed Predicting response to anti-TNF agents for the treatment of Crohn's disease Ther Adv Gastroenterol 2 2009 245 251
3. A. Nesbitt, G. Fossati, M. Bergin, and et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents Inflamm Bowel Dis 13 2007 1323 1332
4. D. Tracey, L. Klareskog, E.H. Sasso, and et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 2008 244 279
5. W.J. Sandborn, and S.R. Targan Biologic therapy of inflammatory bowel disease Gastroenterology 122 2002 1592 1608
6. P. Rutgeerts, S. Vermeire, and G. Van Assche Biological therapies for inflammatory bowel diseases Gastroenterology 136 2009 1182 1197
7. W.J. Sandborn, S.B. Hanauer, S. Katz, and et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
8. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, and et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate N Engl J Med 340 1999 253 259
9. C.L. Leonardi, J.L. Powers, R.T. Matheson, and et al. Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
10. B. Vandooren, E. Kruithof, D.T. Yu, and et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy Arthritis Rheum 50 2004 2942 2953
11. P.T. Elkington, and J.S. Friedland Matrix metalloproteinases in destructive pulmonary pathology Thorax 61 2006 259 266
12. P. Biancheri, A. Di Sabatino, G.R. Corazza, and et al. Proteases and the gut barrier Cell Tissue Res 351 2013 269 280
13. E. Shimshoni, D. Yablecovitch, L. Baram, and et al. ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation Gut 64 2015 367 372
14. M.D. Baugh, M.J. Perry, A.P. Hollander, and et al. Matrix metalloproteinase levels are elevated in inflammatory bowel disease Gastroenterology 117 1999 814 822
15. R.J. Brezski, O. Vafa, D. Petrone, and et al. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge Proc Natl Acad Sci U S A 106 2009 17864 17869
16. R.J. Brezski, and R.E. Jordan Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity? MAbs 2 2010 212 220
17. X. Fan, R.J. Brezski, M. Fa, and et al. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy Breast Cancer Res 14 2012 R116
18. M. Kinder, A.R. Greenplate, K.D. Grugan, and et al. Engineered protease-resistant antibodies with selectable cell-killing functions J Biol Chem 288 2013 30843 30854
19. B.G. Levesque, W.J. Sandborn, J. Ruel, and et al. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice Gastroenterology 148 2015 37 51
20. P.S. Kabouridis, M. Hasan, J. Newson, and et al. Inhibition of NF-kappa B activity by a membrane-transducing mutant of I kappa B alpha J Immunol 169 2002 2587 2593
21. R.J. Brezski, J.L. Luongo, D. Petrone, and et al. Human anti-IgG1 hinge autoantibodies reconstitute the effector functions of proteolytically inactivated IgGs J Immunol 181 2008 3183 3192
22. T. Rispens, H. de Vrieze, E. de Groot, and et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing J Immunol Methods 375 2012 93 99
23. K.S. Nanda, A.S. Cheifetz, and A.C. Moss Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis Am J Gastroenterol 108 2013 40 47
24. I. Ordás, D.R. Mould, B.G. Feagan, and et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms Clin Pharmacol Ther 91 2012 635 646
25. R.J. Brezski, A. Oberholtzer, B. Strake, and et al. The in vitro resistance of IgG2 to proteolytic attack concurs with a comparative paucity of autoantibodies against peptide analogs of the IgG2 hinge MAbs 3 2011 558 567
26. R.A. Clynes, T.L. Towers, L.G. Presta, and et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets Nat Med 6 2000 443 446
27. E. Louis, Z. El Ghoul, S. Vermeire, and et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease Aliment Pharmacol Ther 19 2004 511 519
28. A.C. Vos, M.E. Wildenberg, M. Duijvestein, and et al. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner Gastroenterology 140 2011 221 230
29. A.C. Vos, M.E. Wildenberg, I. Arijs, and et al. Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro Inflamm Bowel Dis 18 2012 401 408
30. S. Akilesh, G.J. Christianson, D.C. Roopenian, and et al. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism J Immunol 179 2007 4580 4588
31. S.L. Pender, and T.T. MacDonald Matrix metalloproteinases and the gut - new roles for old enzymes Curr Opin Pharmacol 4 2004 546 550
32. W.J. Sandborn, J.F. Colombel, B.E. Sands, and et al. Abatacept for Crohn's disease and ulcerative colitis Gastroenterology 143 2012 62 69
33. W. Afif, E.V. Loftus, W.A. Faubion, and et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease Am J Gastroenterol 105 2010 1133 1139
34. S. Ben-Horin, U. Kopylov, and Y. Chowers Optimizing anti-TNF treatments in inflammatory bowel disease Autoimmun Rev 13 2014 24 30
35. N. Vande Casteele, B.G. Feagan, A. Gils, and et al. Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives Curr Gastroenterol Rep 16 2014 378
36. P. Biancheri, N. Powell, G. Monteleone, and et al. The challenges of stratifying patients for trials in inflammatory bowel disease Trends Immunol 34 2013 564 571
37. D.J. Gibson, Z.S. Heetun, C.E. Redmond, and et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis Clin Gastroenterol Hepatol 13 2015 330 335